Pricing Log in Create free account
Friday 6 November 2026 Export TNON’s income statement to Excel — free account

Tenon Medical, Inc.

TNON Healthcare Medical Devices

Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024.

Revenue
+126.8%
EPS
+1.88%
Free cash flow
−21.8%

Quarter to June 2026, against a year earlier

1.66 0.02 +1.22%
Market cap
$4.4M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−13.00
Beneish M
−1.81
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.50
Sold, $m 0.61
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — 1 3 — —
Sell — — — — — — — — 2 3 — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 4.41
Revenue ttm 5.31
Net income ttm (13.70)
Free cash flow ttm (12.82)
Net debt Q (1.68)
Valuation
P/E 0.00
Forward P/E (0.12) (negative: loss-making)
Price / sales 0.10
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.58 (below 1: weak)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (3.94)
Growth
Revenue growth Q +126.77% (above 0%: growing)
Operating income growth Q −17.40% (below 0%: shrinking)
EPS, this year +64.29% (at or above 15%: strong)
EPS, next year A +77.08% (at or above 15%: strong)
Revenue, next year A +52.64% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +71.34% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.2×, against a ten-year median of 0.1×; over the ten years it ranged from −3.2× in 2022 to 92.0× in 2022.
P/S against its own 10 years 0.18%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 7 4 2
Receivables 1 1 2 2
Inventory 1 1 1 1
Other — — — —
4 8 7 5
2023 2024 2025 Q'26
Payables 0 0 1 1
ST’ Debt — — — —
Other 0 0 1 1
3 2 3 8

Compound Annual Growth %

10y 5y 3y
Sales — 145.98% 78.71%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (6.93%)

EPS $

Mar Jun Sep Dec Year
’26 (10.84) (12.35) — — —
’25 (35.31) (12.59) (13.99) (9.80) (59.44)
’24 (349.65) (285.31) (126.92) (34.27) (393.71)
’23 (1.20k) (923.08) (408.39) (344.40) (2.40k)
’22 (6.66k) (1.82k) (783.22) (1.96k) (6.60k)
’21 (677.39) (5.64k) (7.19k) (8.42k) (2.73k)
’20 — — — — (248.50)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 1 — — —
’25 1 1 1 1 4
’24 1 1 1 1 3
’23 0 1 1 1 3
’22 0 0 0 0 1
’21 0 0 0 0 0
’20 — — — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (2) (2) (4) (2) (11)
’24 (2) (2) (2) (3) (10)
’23 (4) (3) (3) (2) (12)
’22 (2) (3) (3) (3) (12)
’21 0 (1) (1) (2) (4)
’20 — — — 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (2) (2) (4) (2) (12)
’24 (2) (2) (2) (3) (10)
’23 (4) (3) (3) (2) (13)
’22 (3) (3) (3) (4) (13)
’21 0 (1) (1) (2) (4)
’20 — — — 0 0
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 0 0 0 1 3 3 4 5 +104.7% 6 9 18 +66.2%
Gross margin, % — — — 66.04 58.45 65.63 (92.76) 42.38 52.21 59.79 66.81 (6.2) pt
EBT — — — (1) (1) (7) (19) (16) (14) (13) (14) +66.7%
EBT margin, % — — — (1,092.91) (1,610.50) (4,425.63) (2,737.63) (532.14) (417.24) (318.36) (257.85) +774.6 pt
Net income — — — (1) (1) (7) (19) (16) (14) (13) (14) +70.6%
Per share, $
Per share, $ Revenue — — — 0.05 18.47 62.04 238.28 450.46 94.44 18.67 16.20 +170.5%
Earnings — — — (0.45) (248.50) (2,733.50) (6,601.40) (2,402.80) (393.71) (59.44) (46.98) +125.7%
Cash flow — — — (0.21) (70.59) (1,664.16) (4,146.55) (1,874.31) (284.67) (50.88) (35.87) +149.8%
Capex — — — 0.00 0.00 (39.55) (292.07) (55.54) (5.36) (4.84) (3.23) n/m
Free cash flow — — — (0.21) (70.59) (1,703.71) (4,438.62) (1,929.85) (290.03) (55.72) (39.10) +153.6%
Book value — — — (2.32) (901.10) (2,680.41) 2,155.86 119.69 172.07 23.86 (5.31) n/m
Shares, m — — — 1 0 0 0 0 0 0 0 (24.3%)
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 116.67 116.67 116.67 18.69 0.96 0.70 1.78 0.10 53.2
P/B — — — 0.00 0.00 0.00 2.07 3.63 1.03 3.58 0.00 1.5
EV/Sales — — — 96.57 96.57 96.57 6.77 0.25 (1.20) 0.92 (0.15) 42.3
EV/FCF — — — (3.06) (3.06) (3.06) (0.36) (0.06) 0.39 (0.31) 0.06 (1.4)
Cash, $m
Cash, $m Operating cash flow — — — 0 0 (4) (12) (12) (10) (11) (12) +89.1%
Capex — — — — — 0 (1) 0 0 (1) (1) +78.0%
Free cash flow — — — 0 0 (4) (13) (13) (10) (12) (13) +92.0%
Balance, $m
Balance, $m Working capital — — — (1) (1) (8) 7 1 6 4 (3) n/m
Net debt — — — 1 0 (7) (9) (2) (7) (4) (2) n/m
Shareholders’ equity — — — (3) (2) (7) 6 1 6 5 (2) n/m
Returns, %
Returns, % ROA — — — 0.00 (177.49) (145.88) (185.82) (178.74) (168.93) (121.89) (130.22) (121.9) pt
ROIC — — — 0.00 0.00 0.00 0.00 0.00 0.00 (622.66) 0.00 (622.7) pt
ROE — — — 0.00 16.06 58.83 264.57 (443.27) (912.45) (600.05) 1,475.97 (600.0) pt
People
People Employees — — — — — 10 22 21 27 26 — +27.0%
Revenue/emp, $m — — — 0.00 0.00 0.02 0.03 0.14 0.12 0.15 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Tenon Medical, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TBIO Telesis Bio Inc. $5.3M — (loss-making) — (loss-making) −71.85% (below 0%: shrinking) n/m −17.96% (below 0%: shrinking) 64.43% (349.74%) Compare
VNRX VolitionRX Limited $5.3M — (loss-making) — (loss-making) −1.97% (below 0%: shrinking) n/m +18.58% (above 0%: growing) 100.00% (1,042.39%) Compare
BDMD Baird Medical Investment Holdings Limited $5.0M — (loss-making) — — n/m −598.12% (below 0%: shrinking) — — Compare
NVNO enVVeno Medical Corporation $4.8M — (loss-making) — (loss-making) +0.32% (above 0%: growing) n/m +27.64% (above 0%: growing) 0.00% 0.00% Compare
TNON Tenon Medical, Inc. $4.4M — (loss-making) — (loss-making) +126.77% (above 0%: growing) n/m −21.78% (below 0%: shrinking) 63.64% (262.24%)
WOK WORK Medical Technology Group LTD $4.1M — — — — −948.94% (below 0%: shrinking) — — Compare
TRIB Trinity Biotech PLC $3.8M — (loss-making) — (loss-making) +43.28% (above 0%: growing) n/m +75.24% (above 0%: growing) 35.43% (24.53%) Compare
XAIR Beyond Air, Inc. $3.6M — (loss-making) — (loss-making) +0.45% (above 0%: growing) n/m −9.10% (below 0%: shrinking) 12.73% (373.98%) Compare
VVOS Vivos Therapeutics, Inc. $3.5M — (loss-making) — (loss-making) +34.90% (above 0%: growing) n/m +16.44% (above 0%: growing) 57.31% (93.63%) Compare
Median of peers $4.5M — — +0.39% — +3.67% 46.37% (221.68%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 23 June 2026

Ownership

Directors and executive officers, together 16.80%
Dr. James Chappuis 9.10%
Norton Capital LLC 9.10%
MNAZ Investment Properties 9.10%
Vantage FBO Jonathan Fitzhugh Beneficiary IRA 9.10%
Vantage FBO Todd Douma IRA 9.10%
The 9.10%
SiVantage, Inc. 7.90%
Wyatt Geist, Chief Innovation Officer 5.30%
Nathaniel Grawey, Chief Commercial Officer 4.70%
Ascent Special Ventures LLC 1.70%
The Beckham-Shufeldt Family Trust 1.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Tenon Medical, Inc. (TNON) Latest News

29 Oct

Impact 3 · · ACCESS Newswire

28 Oct

Impact 4 · · ACCESS Newswire

15 Oct

Impact 4 · · ACCESS Newswire

30 Sep

Impact 4 · · ACCESS Newswire

9 Sep

Impact 3 ·

31 Aug

Impact 3 ·
Impact 3 ·

28 Aug

Impact 3 ·

20 Aug

Impact 4 · · The Motley Fool transcript

14 Aug

Impact 4 ·

13 Aug

Impact 3 · · Moby transcript
Impact 3 ·

20 Jul

Impact 3 ·

2 Jul

Impact 4 ·

1 Jul

Impact 3 ·
Impact 3 ·

30 Jun

Impact 3 ·
Impact 3 ·

13 May

Impact 4 · · GuruFocus.com

12 May

Impact 3 · · Moby
Impact 3 · · ACCESS Newswire

19 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 4 ·

12 Mar

Impact 4 · · PR Newswire
Impact 4 ·

18 Feb

Impact 4 · · ACCESS Newswire

9 Feb

Impact 3 · · Associated Press Finance

5 Feb

Impact 3 · · ACCESS Newswire
stockrow.com/TNON · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com